The DOI matches its Crossref record.
Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias
Abstract
Purpose: Vascular endothelial growth factor (VEGF) promotes acute myelogenous leukemia (AML) cell growth and survival and may contribute to drug resistance. bevacizumab, an anti-VEGF monoclonal antibody, exhibits clinical activity against diverse malignancies when administered with cytotoxic chemotherapy. We conducted a Phase II clinical trial of bevacizumab administered after chemotherapy to adults with refractory or relapsed AML, using a timed sequential therapy (TST) approach. Experimental Design: bevacizumab 10 mg/kg was administered on day 8 after 1-β-d-arabinofuranosylcytosine 2 g/m2/72 h beginning day 1 and mitoxantrone 40 mg/m2 beginning day 4. In vivo laboratory correlates included AML cell VEGF receptor-1 (FLT-1) expression, marrow microvessel density, and free serum VEGF before and during TST with bevacizumab. Results: Forty-eight adults received induction therapy. Myelosuppression occurred in all of the patients similar to other TST regimens. Toxicities were decreased ejection fraction (6%), cerebrovascular bleed (4%), and mortality of 15%. Overall response was 23 of 48 (48%), with complete response (CR) in 16 (33%). Eighteen (14 CR and 4 partial response) underwent one consolidation cycle and 5 (3 CR and 2 partial response) underwent allogeneic transplant. Median overall and disease-free survivals for CR patients were 16.2 months (64%, 1 year) and 7 months (35%, 1 year). Marrow blasts demonstrated FLT-1 staining before bevacizumab and marked decrease in microvessel density after bevacizumab. VEGF was detected in pretreatment serum in 67% of patients tested, increased by day 8 in 52%, and decreased in 93% (67% undetectable) 2 h after bevacizumab. Conclusions: In this single arm study, cytotoxic chemotherapy followed by bevacizumab yields a favorable CR rate and duration in adults with AML that is resistant to traditional treatment approaches. The clearance of marrow blasts in some patients after bevacizumab suggests that VEGF neutralization might result directly in leukemic cell death. The potential biological and clinical activity of bevacizumab in AML warrants additional clinical and laboratory study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Adverse effects of anticancer agents that target the VEGF pathway
Chen, H. X., & Cleck, J. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.94 · Cited by 560
Self-citationPossible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Verheul, H. M. W., & Pinedo, H. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2152 · Cited by 503
Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting
Konopleva, M. Y., & Jordan, C. T. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.0904 · Cited by 402
Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393
Patel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., Hermann, R. C., Jotte, R. M., Beck, T., Richards, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9626 · Cited by 370
Metadata
- Authors
- Karp, J. E., Gojo, I., Pili, R., Gocke, C. D., Greer, J., Guo, C., Qian, D., Morris, L., Tidwell, M., Chen, H., & Zwiebel, J.
- Venue
- Clinical Cancer Research
- Published
- 2004-06-01
- Volume
- 10
- Issue
- 11
- Pages
- 3577-3585
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2150763257
- Cited by
- 180
- References
- 0
- FWCI
- 9.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-03-0627
- The paper
- Karp, J. E., Gojo, I., Pili, R., Gocke, C. D., Greer, J., Guo, C., Qian, D., Morris, L., Tidwell, M., Chen, H., & Zwiebel, J. (2004). Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-03-0627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.